Listed

Adaptimmune Therapeutics PLC: Form 10-K for the period ended Dec 31, 2020

Filed with the SEC on Feb 25, 2021 and accepted by EDGAR at Feb 25, 2021, 16:18 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2020-01-01 to 2020-12-31$4.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development12 months2020-01-01 to 2020-12-31$91.6mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2020-01-01 to 2020-12-31−$133.4mus-gaap:OperatingIncomeLoss
Income tax12 months2020-01-01 to 2020-12-31$162.0kus-gaap:IncomeTaxExpenseBenefit
Net income12 months2020-01-01 to 2020-12-31−$130.1mus-gaap:NetIncomeLoss
Operating cash flow12 months2020-01-01 to 2020-12-31−$53.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2020-01-01 to 2020-12-31$2.3mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2020-12-31$56.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-12-31$398.2mus-gaap:AssetsCurrent
Total assetsAt period end2020-12-31$451.1mus-gaap:Assets
Current liabilitiesAt period end2020-12-31$39.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-12-31$109.9mus-gaap:Liabilities
Shareholders' equityAt period end2020-12-31$341.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001558370-21-001827. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.